Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Topical Solution for the Treatment of Atopic Dermatitis (CYCLATOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02865356
Recruitment Status : Completed
First Posted : August 12, 2016
Last Update Posted : April 17, 2018
Sponsor:
Collaborators:
Germans Trias i Pujol Hospital
Hospital del Mar
Hospital Sant Joan de Deu
Hospital Universitario Virgen Macarena
Hospital Universitario La Fe
Hospital General Universitario de Alicante
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Hospital Universitario Virgen de la Victoria
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Information provided by (Responsible Party):
Spherium Biomed

Tracking Information
First Submitted Date  ICMJE August 4, 2016
First Posted Date  ICMJE August 12, 2016
Last Update Posted Date April 17, 2018
Study Start Date  ICMJE September 2016
Actual Primary Completion Date April 12, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 9, 2016)
  • Absolute change from baseline (Day 0) of Eczema Area and Severity Index (EASI) score of the treated body area (CsA vs Vehicle control placebo) [ Time Frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4). ]
  • Change from baseline (Day 0) of Investigator's Global Assessment (IGA) score (on a 0 to 4-point scale; CsA vs Vehicle control placebo) [ Time Frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4). ]
  • Absolute change from baseline (Day 0) of Atopic Dermatitis Severity Index (ADSI) score (Cs vs Vehicle control placebo) [ Time Frame: Absolute change from Day 0 (baseline) to Day 7 (Visit 1), Day 14 (Visit 2), Day 21(Visit 3) and Day 28 (Visit 4). ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02865356 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 9, 2016)
  • Frequency and severity of treatment-emergent adverse events (TEAEs). [ Time Frame: From date of randomization (Day 0) until 6 weeks ]
  • Frequency and severity of TEAEs leading to study drug discontinuation [ Time Frame: From date of randomization (Day 0) until 6 weeks ]
  • CsA plasma concentrations [ Time Frame: From date of randomization (Day 0) up to 4 weeks, on day 7 and 28. ]
    samples obtained just before the first daily dose (around 8 am) on Visits 0, 1 and 4 to check the absence of systemic absorption during the period of treatment.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Topical Solution for the Treatment of Atopic Dermatitis
Official Title  ICMJE Evaluation of SP14019-F-01 Topical Solution for the Treatment of Atopic Dermatitis. Pilot Study (CYCLATOP STUDY)
Brief Summary

The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments.

Three age cohorts of patients will be included in the study according to the following age ranges:

  1. ≥18 years old (minimum 6, maximum 18 patients)
  2. >12 - 17 years old (minimum 6, maximum 18 patients)
  3. >2 - 12 years old (minimum 6, maximum 18 patients)

The main objectives of study are:

To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to placebo topical solution for the treatment of patients with mild to moderate atopic dermatitis (AD).

To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients with mild to moderate AD.

Detailed Description

The study is designed as a proof of concept, multi-center, randomized, double-blind and vehicle-controlled study with intra-individual comparison of treatments. CsA plasma concentration assessments will be carried out at Visit 0 predose, and Visits 1 and 4 of the study period.

Three age cohorts of patients will be included in the study according to the following age ranges:

  1. ≥18 years old (minimum 6, maximum 18 patients)
  2. >12 - 17 years old (minimum 6, maximum 18 patients)
  3. >2 - 12 years old (minimum 6, maximum 18 patients) The study will close when the total of 36 patients has been included among all age groups and the minimum number of 6 patients has been reached for each age group.

Before including paediatric population, a minimum of 6 adult patients should complete the treatment to assess the safety profile.

A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication (SP14019-F-01 topical solution [5% CsA] or SP14019-F-02 vehicle-control placebo solution). Solutions will be applied twice daily for four complete weeks (28 days) in all affected areas.

Photography will be used to record the evolution of the lesions at Visits 0 (pre-1st dose), Visits 1, 2, 3, 4 and follow-up.

The main objectives of study are:

To assess the efficacy of SP14019-F-01 topical solution (5% cyclosporine A [CsA]) compared to placebo topical solution for the treatment of patients with mild to moderate atopic dermatitis (AD).

To evaluate the safety and tolerability of SP14019-F-01 (5% CsA) topical solution in patients with mild to moderate AD.

A Steering Committee will convene periodically to maintain the quality of study conduct, and to discuss any major issues or concerns and with particular attention to some critical events which may lead to stop the recruitment. These critical events are the observation of either new unexpected signals on safety related to CsA. The Steering Committee will also evaluate the safety profile of the treatment before including paediatric population

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Atopic Dermatitis
Intervention  ICMJE
  • Drug: Cyclosporine 5% solution
    topical solution
    Other Name: ciclosporin
  • Drug: Placebo
    topical vehicle solution
    Other Name: SP14019-F-02 Placebo
Study Arms  ICMJE
  • Experimental: Cyclosporine 5% Solution

    SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.

    A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication

    Intervention: Drug: Cyclosporine 5% solution
  • Placebo Comparator: Placebo

    SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.

    A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication

    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 9, 2016)
36
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 12, 2017
Actual Primary Completion Date April 12, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female aged between 2 and 75 years, inclusive, at the screening visit. 2. AD diagnosis according to the Hanifin/Rajka criteria with one eczema outbreak at the screening and baseline.

    3. Presence of at least two lesional areas. These areas should be at the left and right side of the body and occupying a body surface area (BSA) in each side between 0.1% and 10% of the BSA. IGA score of the two sites not differ by more than 1 point.

    4. Mild to moderate disease severity of AD defined by an IGA score of 2 or 3 at baseline (IGA scale from 0 to 4).

    5. Total BSA of AD involvement ≤ 10% in each side of the body (≤ 20% maximum). 6. Normal weight as defined by a Quetelet Index (Body Mass Index [BMI]: weight in kg divided by the square of height in meters) of 18.0 to 30.0 kg/m2 (both included).

    7. General medical condition, in the investigator's opinion, does not interfere with the assessments and the completion of the trial.

    8. Parent's or legal guardian's written informed consent and child assent, if appropriate or patient's inform consent for patients ≥ 18 years of age before any assessment is performed.

    9. Able to communicate with the investigator and comply with the requirements of the study (for children the parent can assist when necessary).

Exclusion Criteria:

  • 1. Female subject of childbearing potential without use of effective birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period;

Note: Estrogen based hormonal contraception may not be reliable when SP14019-F-01 topical solution is applied, therefore to be eligible for this trial, women of childbearing potential should either:

  1. use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap);
  2. use hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
  3. use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
  4. be only non-heterosexually active, practice heterosexual abstinence, or have a vasectomized partner (confirmed sterile). Women with tubal ligation are required to use 1 non-hormonal contraceptive method.

    Women who are postmenopausal for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential. Males with partners of childbearing potential should inform them of their participation in this clinical study and use a highly effective method of birth control during the study.

    2. Pregnant woman or with a positive pregnancy test or breast feeding at baseline.

    3. Any condition in the lesions that in the opinion of the investigator could interfere with clinical assessments, e.g. acne, infection, rash other than AD, sunburn, scars, hairy or tattooed area.

    4. Patients receiving phototherapy or systemic therapy for AD within 4 weeks before the first application of trial medication.

    5. Patients receiving antibiotics, topical therapy for AD within 2 weeks before the first application of trial medication.

    6. Patients taking antihistamines within 1 week before the first application of trial medication.

    7. Patients receiving radiation therapy, systemic therapy with cytostatics or biological therapy within 24 weeks before the first application of trial medication, or with previous history of malignancy (excluding basal cell carcinoma).

    8. Patients with any acute skin infection (superinfection or secondary impetiginisation).

    9. Patients with confirmed hypertension, renal disease or serious infections at screening.

    10. Any currently active allergy such as but not limited to drug allergy, food allergy or hay fever.

    11. Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the trial medication administered in this trial.

    12. Participation in an investigational drug trial within 30 days prior to the first application of trial medication.

    13. Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the patient safety or compliance with trial procedures.

    14. Subjects who have received or are planning to receive any vaccination within 28 days prior to the first dose of study medication, or planning to receive a vaccination during the course of the study.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 2 Years to 75 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02865356
Other Study ID Numbers  ICMJE SP14019-18
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Spherium Biomed
Study Sponsor  ICMJE Spherium Biomed
Collaborators  ICMJE
  • Germans Trias i Pujol Hospital
  • Hospital del Mar
  • Hospital Sant Joan de Deu
  • Hospital Universitario Virgen Macarena
  • Hospital Universitario La Fe
  • Hospital General Universitario de Alicante
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
  • Hospital Universitario Virgen de la Victoria
  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Investigators  ICMJE
Principal Investigator: Carlos Ferrándiz, MD, PhD Germans Trias i Pujol Hospital
PRS Account Spherium Biomed
Verification Date April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP